nodes	percent_of_prediction	percent_of_DWPC	metapath
Sulindac—CYP1A2—Carmustine—lymphatic system cancer	0.114	0.584	CbGbCtD
Sulindac—SLC22A6—Methotrexate—lymphatic system cancer	0.0438	0.225	CbGbCtD
Sulindac—ALB—Methotrexate—lymphatic system cancer	0.0373	0.191	CbGbCtD
Sulindac—Stomatitis—Vincristine—lymphatic system cancer	0.00188	0.00234	CcSEcCtD
Sulindac—Protein urine present—Methotrexate—lymphatic system cancer	0.00188	0.00233	CcSEcCtD
Sulindac—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00187	0.00233	CcSEcCtD
Sulindac—Chills—Bleomycin—lymphatic system cancer	0.00187	0.00232	CcSEcCtD
Sulindac—Sweating—Vincristine—lymphatic system cancer	0.00185	0.0023	CcSEcCtD
Sulindac—Renal failure—Mitoxantrone—lymphatic system cancer	0.00185	0.00229	CcSEcCtD
Sulindac—Nausea—Mechlorethamine—lymphatic system cancer	0.00185	0.00229	CcSEcCtD
Sulindac—Alopecia—Bleomycin—lymphatic system cancer	0.00184	0.00228	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00184	0.00228	CcSEcCtD
Sulindac—Stomatitis—Mitoxantrone—lymphatic system cancer	0.00183	0.00228	CcSEcCtD
Sulindac—Jaundice—Mitoxantrone—lymphatic system cancer	0.00183	0.00228	CcSEcCtD
Sulindac—Conjunctivitis—Mitoxantrone—lymphatic system cancer	0.00183	0.00227	CcSEcCtD
Sulindac—Urticaria—Teniposide—lymphatic system cancer	0.00182	0.00226	CcSEcCtD
Sulindac—Glossitis—Methotrexate—lymphatic system cancer	0.00182	0.00226	CcSEcCtD
Sulindac—Body temperature increased—Teniposide—lymphatic system cancer	0.00181	0.00225	CcSEcCtD
Sulindac—Paraesthesia—Fludarabine—lymphatic system cancer	0.00181	0.00225	CcSEcCtD
Sulindac—Sweating—Mitoxantrone—lymphatic system cancer	0.0018	0.00224	CcSEcCtD
Sulindac—Dyspnoea—Fludarabine—lymphatic system cancer	0.0018	0.00223	CcSEcCtD
Sulindac—Haematuria—Mitoxantrone—lymphatic system cancer	0.00179	0.00223	CcSEcCtD
Sulindac—Dyspepsia—Fludarabine—lymphatic system cancer	0.00177	0.0022	CcSEcCtD
Sulindac—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.00175	0.00218	CcSEcCtD
Sulindac—Decreased appetite—Fludarabine—lymphatic system cancer	0.00175	0.00218	CcSEcCtD
Sulindac—Visual impairment—Carmustine—lymphatic system cancer	0.00175	0.00217	CcSEcCtD
Sulindac—Fatigue—Fludarabine—lymphatic system cancer	0.00174	0.00216	CcSEcCtD
Sulindac—Constipation—Fludarabine—lymphatic system cancer	0.00172	0.00214	CcSEcCtD
Sulindac—Hypersensitivity—Teniposide—lymphatic system cancer	0.00169	0.0021	CcSEcCtD
Sulindac—Hepatitis—Mitoxantrone—lymphatic system cancer	0.00169	0.0021	CcSEcCtD
Sulindac—Flushing—Carmustine—lymphatic system cancer	0.00168	0.00209	CcSEcCtD
Sulindac—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00168	0.00209	CcSEcCtD
Sulindac—Anaemia—Bleomycin—lymphatic system cancer	0.00167	0.00208	CcSEcCtD
Sulindac—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00166	0.00206	CcSEcCtD
Sulindac—Asthenia—Teniposide—lymphatic system cancer	0.00164	0.00204	CcSEcCtD
Sulindac—Malaise—Bleomycin—lymphatic system cancer	0.00163	0.00203	CcSEcCtD
Sulindac—Pruritus—Teniposide—lymphatic system cancer	0.00162	0.00201	CcSEcCtD
Sulindac—Arrhythmia—Carmustine—lymphatic system cancer	0.00162	0.00201	CcSEcCtD
Sulindac—Leukopenia—Bleomycin—lymphatic system cancer	0.00162	0.00201	CcSEcCtD
Sulindac—Depressed level of consciousness—Methotrexate—lymphatic system cancer	0.00162	0.00201	CcSEcCtD
Sulindac—Alopecia—Carmustine—lymphatic system cancer	0.0016	0.00199	CcSEcCtD
Sulindac—Body temperature increased—Fludarabine—lymphatic system cancer	0.00159	0.00198	CcSEcCtD
Sulindac—Aplastic anaemia—Methotrexate—lymphatic system cancer	0.00157	0.00195	CcSEcCtD
Sulindac—Diarrhoea—Teniposide—lymphatic system cancer	0.00157	0.00195	CcSEcCtD
Sulindac—Myalgia—Bleomycin—lymphatic system cancer	0.00154	0.00191	CcSEcCtD
Sulindac—Chest pain—Bleomycin—lymphatic system cancer	0.00154	0.00191	CcSEcCtD
Sulindac—Alopecia—Vincristine—lymphatic system cancer	0.00153	0.0019	CcSEcCtD
Sulindac—Coma—Methotrexate—lymphatic system cancer	0.00153	0.0019	CcSEcCtD
Sulindac—Discomfort—Bleomycin—lymphatic system cancer	0.00152	0.00189	CcSEcCtD
Sulindac—Chills—Mitoxantrone—lymphatic system cancer	0.00151	0.00188	CcSEcCtD
Sulindac—Ecchymosis—Methotrexate—lymphatic system cancer	0.00151	0.00188	CcSEcCtD
Sulindac—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00151	0.00187	CcSEcCtD
Sulindac—Gynaecomastia—Methotrexate—lymphatic system cancer	0.0015	0.00186	CcSEcCtD
Sulindac—Alopecia—Mitoxantrone—lymphatic system cancer	0.00149	0.00185	CcSEcCtD
Sulindac—Vision blurred—Carmustine—lymphatic system cancer	0.00149	0.00185	CcSEcCtD
Sulindac—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00148	0.00184	CcSEcCtD
Sulindac—Oedema—Bleomycin—lymphatic system cancer	0.00148	0.00183	CcSEcCtD
Sulindac—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00148	0.00183	CcSEcCtD
Sulindac—Anaemia—Carmustine—lymphatic system cancer	0.00146	0.00181	CcSEcCtD
Sulindac—Vomiting—Teniposide—lymphatic system cancer	0.00146	0.00181	CcSEcCtD
Sulindac—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00145	0.0018	CcSEcCtD
Sulindac—Asthenia—Fludarabine—lymphatic system cancer	0.00145	0.0018	CcSEcCtD
Sulindac—Rash—Teniposide—lymphatic system cancer	0.00145	0.0018	CcSEcCtD
Sulindac—Dermatitis—Teniposide—lymphatic system cancer	0.00144	0.00179	CcSEcCtD
Sulindac—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00144	0.00179	CcSEcCtD
Sulindac—Headache—Teniposide—lymphatic system cancer	0.00144	0.00178	CcSEcCtD
Sulindac—Pruritus—Fludarabine—lymphatic system cancer	0.00143	0.00177	CcSEcCtD
Sulindac—Leukopenia—Carmustine—lymphatic system cancer	0.00141	0.00176	CcSEcCtD
Sulindac—Anorexia—Bleomycin—lymphatic system cancer	0.00141	0.00175	CcSEcCtD
Sulindac—Anaemia—Vincristine—lymphatic system cancer	0.00139	0.00173	CcSEcCtD
Sulindac—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00138	0.00172	CcSEcCtD
Sulindac—Photosensitivity—Methotrexate—lymphatic system cancer	0.00138	0.00172	CcSEcCtD
Sulindac—Hypotension—Bleomycin—lymphatic system cancer	0.00138	0.00171	CcSEcCtD
Sulindac—Diarrhoea—Fludarabine—lymphatic system cancer	0.00138	0.00171	CcSEcCtD
Sulindac—Convulsion—Carmustine—lymphatic system cancer	0.00137	0.0017	CcSEcCtD
Sulindac—Hypertension—Carmustine—lymphatic system cancer	0.00136	0.00169	CcSEcCtD
Sulindac—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00136	0.00169	CcSEcCtD
Sulindac—Nausea—Teniposide—lymphatic system cancer	0.00136	0.00169	CcSEcCtD
Sulindac—Anaemia—Mitoxantrone—lymphatic system cancer	0.00136	0.00169	CcSEcCtD
Sulindac—Vertigo—Vincristine—lymphatic system cancer	0.00135	0.00168	CcSEcCtD
Sulindac—Hepatic failure—Methotrexate—lymphatic system cancer	0.00135	0.00168	CcSEcCtD
Sulindac—Leukopenia—Vincristine—lymphatic system cancer	0.00135	0.00168	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00135	0.00167	CcSEcCtD
Sulindac—Chest pain—Carmustine—lymphatic system cancer	0.00134	0.00167	CcSEcCtD
Sulindac—Myalgia—Carmustine—lymphatic system cancer	0.00134	0.00167	CcSEcCtD
Sulindac—Paraesthesia—Bleomycin—lymphatic system cancer	0.00133	0.00165	CcSEcCtD
Sulindac—Malaise—Mitoxantrone—lymphatic system cancer	0.00132	0.00165	CcSEcCtD
Sulindac—Dyspnoea—Bleomycin—lymphatic system cancer	0.00132	0.00164	CcSEcCtD
Sulindac—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00131	0.00163	CcSEcCtD
Sulindac—Convulsion—Vincristine—lymphatic system cancer	0.00131	0.00162	CcSEcCtD
Sulindac—Hypertension—Vincristine—lymphatic system cancer	0.0013	0.00162	CcSEcCtD
Sulindac—Oedema—Carmustine—lymphatic system cancer	0.00129	0.0016	CcSEcCtD
Sulindac—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.00129	0.0016	CcSEcCtD
Sulindac—Decreased appetite—Bleomycin—lymphatic system cancer	0.00128	0.00159	CcSEcCtD
Sulindac—Myalgia—Vincristine—lymphatic system cancer	0.00128	0.00159	CcSEcCtD
Sulindac—Visual disturbance—Methotrexate—lymphatic system cancer	0.00128	0.00159	CcSEcCtD
Sulindac—Vomiting—Fludarabine—lymphatic system cancer	0.00128	0.00159	CcSEcCtD
Sulindac—Convulsion—Mitoxantrone—lymphatic system cancer	0.00127	0.00158	CcSEcCtD
Sulindac—Rash—Fludarabine—lymphatic system cancer	0.00127	0.00158	CcSEcCtD
Sulindac—Dermatitis—Fludarabine—lymphatic system cancer	0.00127	0.00158	CcSEcCtD
Sulindac—Hypertension—Mitoxantrone—lymphatic system cancer	0.00127	0.00157	CcSEcCtD
Sulindac—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00126	0.00157	CcSEcCtD
Sulindac—Headache—Fludarabine—lymphatic system cancer	0.00126	0.00157	CcSEcCtD
Sulindac—Tachycardia—Carmustine—lymphatic system cancer	0.00126	0.00156	CcSEcCtD
Sulindac—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00125	0.00155	CcSEcCtD
Sulindac—Chest pain—Mitoxantrone—lymphatic system cancer	0.00125	0.00155	CcSEcCtD
Sulindac—Myalgia—Mitoxantrone—lymphatic system cancer	0.00125	0.00155	CcSEcCtD
Sulindac—Discomfort—Mitoxantrone—lymphatic system cancer	0.00124	0.00153	CcSEcCtD
Sulindac—Oedema—Vincristine—lymphatic system cancer	0.00123	0.00153	CcSEcCtD
Sulindac—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00123	0.00153	CcSEcCtD
Sulindac—Anorexia—Carmustine—lymphatic system cancer	0.00123	0.00153	CcSEcCtD
Sulindac—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00122	0.00151	CcSEcCtD
Sulindac—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00121	0.0015	CcSEcCtD
Sulindac—Hypotension—Carmustine—lymphatic system cancer	0.0012	0.0015	CcSEcCtD
Sulindac—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.0012	0.00149	CcSEcCtD
Sulindac—Oedema—Mitoxantrone—lymphatic system cancer	0.0012	0.00149	CcSEcCtD
Sulindac—Nausea—Fludarabine—lymphatic system cancer	0.0012	0.00149	CcSEcCtD
Sulindac—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00119	0.00148	CcSEcCtD
Sulindac—Shock—Mitoxantrone—lymphatic system cancer	0.00118	0.00146	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00117	0.00146	CcSEcCtD
Sulindac—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00117	0.00146	CcSEcCtD
Sulindac—Urticaria—Bleomycin—lymphatic system cancer	0.00117	0.00146	CcSEcCtD
Sulindac—Anorexia—Vincristine—lymphatic system cancer	0.00117	0.00146	CcSEcCtD
Sulindac—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00117	0.00145	CcSEcCtD
Sulindac—Body temperature increased—Bleomycin—lymphatic system cancer	0.00117	0.00145	CcSEcCtD
Sulindac—Insomnia—Carmustine—lymphatic system cancer	0.00117	0.00145	CcSEcCtD
Sulindac—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00116	0.00144	CcSEcCtD
Sulindac—Paraesthesia—Carmustine—lymphatic system cancer	0.00116	0.00144	CcSEcCtD
Sulindac—Hypotension—Vincristine—lymphatic system cancer	0.00115	0.00143	CcSEcCtD
Sulindac—Dyspnoea—Carmustine—lymphatic system cancer	0.00115	0.00143	CcSEcCtD
Sulindac—Somnolence—Carmustine—lymphatic system cancer	0.00115	0.00142	CcSEcCtD
Sulindac—Anorexia—Mitoxantrone—lymphatic system cancer	0.00114	0.00142	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00112	0.00139	CcSEcCtD
Sulindac—Decreased appetite—Carmustine—lymphatic system cancer	0.00112	0.00139	CcSEcCtD
Sulindac—Hypotension—Mitoxantrone—lymphatic system cancer	0.00112	0.00139	CcSEcCtD
Sulindac—Insomnia—Vincristine—lymphatic system cancer	0.00111	0.00138	CcSEcCtD
Sulindac—Paraesthesia—Vincristine—lymphatic system cancer	0.00111	0.00137	CcSEcCtD
Sulindac—Constipation—Carmustine—lymphatic system cancer	0.0011	0.00137	CcSEcCtD
Sulindac—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.00109	0.00136	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00109	0.00136	CcSEcCtD
Sulindac—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00109	0.00135	CcSEcCtD
Sulindac—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00108	0.00134	CcSEcCtD
Sulindac—Decreased appetite—Vincristine—lymphatic system cancer	0.00107	0.00133	CcSEcCtD
Sulindac—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00107	0.00133	CcSEcCtD
Sulindac—Somnolence—Mitoxantrone—lymphatic system cancer	0.00107	0.00132	CcSEcCtD
Sulindac—Feeling abnormal—Carmustine—lymphatic system cancer	0.00106	0.00132	CcSEcCtD
Sulindac—Fatigue—Vincristine—lymphatic system cancer	0.00106	0.00132	CcSEcCtD
Sulindac—Asthenia—Bleomycin—lymphatic system cancer	0.00106	0.00132	CcSEcCtD
Sulindac—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00106	0.00131	CcSEcCtD
Sulindac—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00105	0.00131	CcSEcCtD
Sulindac—Constipation—Vincristine—lymphatic system cancer	0.00105	0.00131	CcSEcCtD
Sulindac—Pruritus—Bleomycin—lymphatic system cancer	0.00104	0.0013	CcSEcCtD
Sulindac—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00104	0.00129	CcSEcCtD
Sulindac—Eosinophilia—Methotrexate—lymphatic system cancer	0.00104	0.00129	CcSEcCtD
Sulindac—Fatigue—Mitoxantrone—lymphatic system cancer	0.00103	0.00128	CcSEcCtD
Sulindac—Pancreatitis—Methotrexate—lymphatic system cancer	0.00103	0.00128	CcSEcCtD
Sulindac—Constipation—Mitoxantrone—lymphatic system cancer	0.00102	0.00127	CcSEcCtD
Sulindac—Body temperature increased—Carmustine—lymphatic system cancer	0.00102	0.00127	CcSEcCtD
Sulindac—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00101	0.00125	CcSEcCtD
Sulindac—Pancytopenia—Methotrexate—lymphatic system cancer	0.000997	0.00124	CcSEcCtD
Sulindac—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000988	0.00123	CcSEcCtD
Sulindac—Neutropenia—Methotrexate—lymphatic system cancer	0.000982	0.00122	CcSEcCtD
Sulindac—Dysuria—Methotrexate—lymphatic system cancer	0.000982	0.00122	CcSEcCtD
Sulindac—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00098	0.00122	CcSEcCtD
Sulindac—Body temperature increased—Vincristine—lymphatic system cancer	0.000973	0.00121	CcSEcCtD
Sulindac—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000959	0.00119	CcSEcCtD
Sulindac—Urticaria—Mitoxantrone—lymphatic system cancer	0.000952	0.00118	CcSEcCtD
Sulindac—Hypersensitivity—Carmustine—lymphatic system cancer	0.00095	0.00118	CcSEcCtD
Sulindac—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000948	0.00118	CcSEcCtD
Sulindac—Pneumonia—Methotrexate—lymphatic system cancer	0.000942	0.00117	CcSEcCtD
Sulindac—Vomiting—Bleomycin—lymphatic system cancer	0.000939	0.00117	CcSEcCtD
Sulindac—Depression—Methotrexate—lymphatic system cancer	0.000934	0.00116	CcSEcCtD
Sulindac—Rash—Bleomycin—lymphatic system cancer	0.000931	0.00116	CcSEcCtD
Sulindac—Dermatitis—Bleomycin—lymphatic system cancer	0.00093	0.00116	CcSEcCtD
Sulindac—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000928	0.00115	CcSEcCtD
Sulindac—Asthenia—Carmustine—lymphatic system cancer	0.000925	0.00115	CcSEcCtD
Sulindac—Renal failure—Methotrexate—lymphatic system cancer	0.00092	0.00114	CcSEcCtD
Sulindac—Stomatitis—Methotrexate—lymphatic system cancer	0.000913	0.00113	CcSEcCtD
Sulindac—Conjunctivitis—Methotrexate—lymphatic system cancer	0.00091	0.00113	CcSEcCtD
Sulindac—Hypersensitivity—Vincristine—lymphatic system cancer	0.000907	0.00113	CcSEcCtD
Sulindac—Sweating—Methotrexate—lymphatic system cancer	0.000898	0.00112	CcSEcCtD
Sulindac—Haematuria—Methotrexate—lymphatic system cancer	0.000893	0.00111	CcSEcCtD
Sulindac—Epistaxis—Methotrexate—lymphatic system cancer	0.000883	0.0011	CcSEcCtD
Sulindac—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000883	0.0011	CcSEcCtD
Sulindac—Asthenia—Vincristine—lymphatic system cancer	0.000883	0.0011	CcSEcCtD
Sulindac—Diarrhoea—Carmustine—lymphatic system cancer	0.000882	0.0011	CcSEcCtD
Sulindac—Nausea—Bleomycin—lymphatic system cancer	0.000877	0.00109	CcSEcCtD
Sulindac—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000874	0.00109	CcSEcCtD
Sulindac—Asthenia—Mitoxantrone—lymphatic system cancer	0.00086	0.00107	CcSEcCtD
Sulindac—Dizziness—Carmustine—lymphatic system cancer	0.000853	0.00106	CcSEcCtD
Sulindac—Diarrhoea—Vincristine—lymphatic system cancer	0.000842	0.00105	CcSEcCtD
Sulindac—Hepatitis—Methotrexate—lymphatic system cancer	0.000841	0.00104	CcSEcCtD
Sulindac—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00082	0.00102	CcSEcCtD
Sulindac—Vomiting—Carmustine—lymphatic system cancer	0.00082	0.00102	CcSEcCtD
Sulindac—Dizziness—Vincristine—lymphatic system cancer	0.000814	0.00101	CcSEcCtD
Sulindac—Rash—Carmustine—lymphatic system cancer	0.000813	0.00101	CcSEcCtD
Sulindac—Dermatitis—Carmustine—lymphatic system cancer	0.000812	0.00101	CcSEcCtD
Sulindac—Visual impairment—Methotrexate—lymphatic system cancer	0.00081	0.00101	CcSEcCtD
Sulindac—Headache—Carmustine—lymphatic system cancer	0.000808	0.001	CcSEcCtD
Sulindac—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000795	0.000987	CcSEcCtD
Sulindac—Tinnitus—Methotrexate—lymphatic system cancer	0.000784	0.000973	CcSEcCtD
Sulindac—Vomiting—Vincristine—lymphatic system cancer	0.000783	0.000972	CcSEcCtD
Sulindac—Rash—Vincristine—lymphatic system cancer	0.000776	0.000964	CcSEcCtD
Sulindac—Dermatitis—Vincristine—lymphatic system cancer	0.000775	0.000963	CcSEcCtD
Sulindac—Headache—Vincristine—lymphatic system cancer	0.000771	0.000958	CcSEcCtD
Sulindac—Nausea—Carmustine—lymphatic system cancer	0.000766	0.000951	CcSEcCtD
Sulindac—Vomiting—Mitoxantrone—lymphatic system cancer	0.000762	0.000947	CcSEcCtD
Sulindac—Rash—Mitoxantrone—lymphatic system cancer	0.000756	0.000939	CcSEcCtD
Sulindac—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000755	0.000938	CcSEcCtD
Sulindac—Chills—Methotrexate—lymphatic system cancer	0.000754	0.000937	CcSEcCtD
Sulindac—Headache—Mitoxantrone—lymphatic system cancer	0.000751	0.000933	CcSEcCtD
Sulindac—Alopecia—Methotrexate—lymphatic system cancer	0.000743	0.000923	CcSEcCtD
Sulindac—Nausea—Vincristine—lymphatic system cancer	0.000731	0.000908	CcSEcCtD
Sulindac—Dysgeusia—Methotrexate—lymphatic system cancer	0.000717	0.00089	CcSEcCtD
Sulindac—Nausea—Mitoxantrone—lymphatic system cancer	0.000712	0.000884	CcSEcCtD
Sulindac—Vision blurred—Methotrexate—lymphatic system cancer	0.00069	0.000857	CcSEcCtD
Sulindac—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000679	0.000843	CcSEcCtD
Sulindac—Anaemia—Methotrexate—lymphatic system cancer	0.000676	0.00084	CcSEcCtD
Sulindac—Malaise—Methotrexate—lymphatic system cancer	0.00066	0.00082	CcSEcCtD
Sulindac—Vertigo—Methotrexate—lymphatic system cancer	0.000657	0.000817	CcSEcCtD
Sulindac—Leukopenia—Methotrexate—lymphatic system cancer	0.000655	0.000814	CcSEcCtD
Sulindac—Convulsion—Methotrexate—lymphatic system cancer	0.000634	0.000787	CcSEcCtD
Sulindac—Chest pain—Methotrexate—lymphatic system cancer	0.000623	0.000774	CcSEcCtD
Sulindac—Arthralgia—Methotrexate—lymphatic system cancer	0.000623	0.000774	CcSEcCtD
Sulindac—Myalgia—Methotrexate—lymphatic system cancer	0.000623	0.000774	CcSEcCtD
Sulindac—Discomfort—Methotrexate—lymphatic system cancer	0.000615	0.000765	CcSEcCtD
Sulindac—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000597	0.000742	CcSEcCtD
Sulindac—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000585	0.000726	CcSEcCtD
Sulindac—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000577	0.000717	CcSEcCtD
Sulindac—Anorexia—Methotrexate—lymphatic system cancer	0.000569	0.000707	CcSEcCtD
Sulindac—Hypotension—Methotrexate—lymphatic system cancer	0.000558	0.000693	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000544	0.000676	CcSEcCtD
Sulindac—Insomnia—Methotrexate—lymphatic system cancer	0.00054	0.000671	CcSEcCtD
Sulindac—Paraesthesia—Methotrexate—lymphatic system cancer	0.000536	0.000666	CcSEcCtD
Sulindac—Dyspnoea—Methotrexate—lymphatic system cancer	0.000532	0.000661	CcSEcCtD
Sulindac—Somnolence—Methotrexate—lymphatic system cancer	0.000531	0.000659	CcSEcCtD
Sulindac—Dyspepsia—Methotrexate—lymphatic system cancer	0.000526	0.000653	CcSEcCtD
Sulindac—Decreased appetite—Methotrexate—lymphatic system cancer	0.000519	0.000645	CcSEcCtD
Sulindac—Fatigue—Methotrexate—lymphatic system cancer	0.000515	0.00064	CcSEcCtD
Sulindac—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000492	0.000611	CcSEcCtD
Sulindac—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000488	0.000607	CcSEcCtD
Sulindac—Urticaria—Methotrexate—lymphatic system cancer	0.000474	0.000589	CcSEcCtD
Sulindac—Body temperature increased—Methotrexate—lymphatic system cancer	0.000472	0.000586	CcSEcCtD
Sulindac—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00044	0.000547	CcSEcCtD
Sulindac—Asthenia—Methotrexate—lymphatic system cancer	0.000428	0.000532	CcSEcCtD
Sulindac—Pruritus—Methotrexate—lymphatic system cancer	0.000423	0.000525	CcSEcCtD
Sulindac—Diarrhoea—Methotrexate—lymphatic system cancer	0.000409	0.000508	CcSEcCtD
Sulindac—Dizziness—Methotrexate—lymphatic system cancer	0.000395	0.000491	CcSEcCtD
Sulindac—Vomiting—Methotrexate—lymphatic system cancer	0.00038	0.000472	CcSEcCtD
Sulindac—Rash—Methotrexate—lymphatic system cancer	0.000377	0.000468	CcSEcCtD
Sulindac—Dermatitis—Methotrexate—lymphatic system cancer	0.000376	0.000467	CcSEcCtD
Sulindac—Headache—Methotrexate—lymphatic system cancer	0.000374	0.000465	CcSEcCtD
Sulindac—Nausea—Methotrexate—lymphatic system cancer	0.000355	0.000441	CcSEcCtD
